knowledge -WSS

knowledge

author：hotspot 2025-09-28 04:58:44 - browse：2251

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Why don't Americans have at

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Report: NIH

First Opinion Podcast: What happens when kids become caregivers?

Stigma and the return of syphilis

Bernie Sanders gets little from pharma CEOs on drug prices

Addiction doctors spar with methadone clinics over legislation

knowledge

knowledge

entertainment

Affirmative action in medical school literally saved lives

Study gives hint on South Asians’ higher risk of cardiovascular disease

How one medical school became remarkably diverse

Adam's Biotech Scorecard: Do Sarepta's exon

ChatGPT in medicine: STAT answers readers' burning questions

Bernie Sanders gets little from pharma CEOs on drug prices

At least 13 dead in Texas as scorching temps continue

David Sabatini, ex

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Resistance to opioid

focus

Readout Newsletter: Amylyx, Aurinia, and IQVIA

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Amylyx, Aurinia, and IQVIA

AMAs digital advisors table RPM coding reform proposal, again

Biohaven protein

Average age of first period drops to 11.9 years, study shows

Wikipedia

entertainment

focus

entertainment